Questions
Fifteen questions about the Epitalon research record, answered directly.
What is Epitalon and where does it come from?
Epitalon is the common name for the synthetic tetrapeptide Alanyl-Glutamyl-Aspartyl-Glycine (AEDG), molecular weight 390.35 Da. It was developed by Vladimir Khavinson's laboratory at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of a sequence identified in Epithalamin — a polypeptide extract of bovine pineal gland that had been studied for aging-related effects since the 1970s. LC-MS/MS analysis confirmed in 2017 that the AEDG sequence is present endogenously in the human pineal gland, suggesting it may be a bioactive fragment of a naturally occurring peptide rather than a wholly foreign molecule [13]. The compound is also called Epithalon or Epithalone in different publications; these refer to the same AEDG tetrapeptide.
What does the published research show about Epitalon and telomere length?
Two lines of evidence exist. Khavinson, Bondarev, and Butyugov (2003) showed that Epitalon induced hTERT expression and restored telomerase enzymatic activity in telomerase-negative human fetal fibroblast cultures, producing measurable telomere elongation [1] — an early report of a peptide reactivating telomerase in normal somatic cells. A 2025 study by Al-dulaimi et al. — from an independent group not affiliated with the Khavinson lab — used Epitalon at 0.2–1 µg/ml in four human cell lines and found differential telomere extension: in normal cells, extension via hTERT upregulation and a 4- to 26-fold telomerase activity increase; in breast cancer cell lines, extension via alternative lengthening of telomeres (ALT), a recombination-based mechanism [2]. The 2025 study is the first independent (non-Russian) published confirmation of Epitalon's telomere-extension capacity in human cells.
How does Epitalon affect melatonin and the pineal gland in research models?
Several mechanisms have been documented. In cultured rat pinealocytes, Epitalon directly modulated AANAT enzyme activity and pCREB transcription factor expression within three hours, stimulating melatonin synthesis more potently than the comparison peptide Vilon [17]. In pinealectomized rats treated for 42 days, it restored hormone-producing cell ratios in the gastrointestinal tract — evidence of systemic downstream effects. In senescent rhesus macaques (ages 20–26), intramuscular Epitalon at 10 µg/kg over 10 days restored evening melatonin elevation and normalized the cortisol circadian pattern [11]. In a human clinical series (75 women, sublingual 0.5 mg/day for 20 days), melatonin excretion increased 1.6-fold and circadian gene expression (Clock, Cry2, Csnk1e) normalized [15]. These effects reversed within one month of cessation in the primate study.
Has Epitalon been studied in human subjects, and what were the findings?
Two published human studies exist, both by the Khavinson group. The first enrolled 162 patients with retinitis pigmentosa and administered 5.0 µg Epitalon per eye by parabulbar injection for 10 consecutive days [12]. Investigators reported a positive clinical response in 90% of patients, mean visual acuity improvement of 0.15–0.20 on the standard scale, and peripheral visual field expansion in 64.8% of patients, with no reported adverse effects. The second enrolled 75 women with accelerated pineal aging and used sublingual Epitalon at 0.5 mg/day for 20 days [15]; results included a 1.6-fold melatonin increase and statistically significant normalization of three circadian clock genes. Both studies are open-label, single-center, and without placebo control. No randomized controlled trial by any group has been published.
What are the main criticisms and limitations of Epitalon research?
The core limitation is source concentration: nearly all published Epitalon research originates from a single institution — the St. Petersburg Institute of Bioregulation and Gerontology — and its collaborators. Independent replication by external laboratories is very limited; the 2025 Al-dulaimi telomere study [2] and the 2025 Gatta retinal wound-healing study [19] are the most significant exceptions. Other limitations include the absence of any randomized controlled trial in humans; no formal pharmacokinetic characterization in any species; missing comprehensive toxicology and genotoxicity data; unexplored stereoisomer pharmacology; and the concentration of the primary lifespan effect in the last-10%-survivor cohort rather than median lifespan [3][4]. The NIA Interventions Testing Program — the gold standard for independent longevity evaluation in rodents — has not tested Epitalon. The theoretical concern about ALT activation in cancer cells [2], while mechanistically unresolved, is also worth noting.
What doses have been used in animal studies of Epitalon?
Doses vary widely across study designs and species. The major rodent lifespan and anti-tumor studies used 1 µg/mouse subcutaneously for 5 consecutive days per month (SHR and FVB/N mice [3][4]) or 0.1 µg/mouse five times weekly for 6.5 months (C3H/He mice [7]). The rat colon carcinogenesis study used 1 µg/rat subcutaneously [6]. The rat renal model used 7 µg/kg intraperitoneally for 7 days [13]. The primate neuroendocrine study used 10 µg/kg intramuscularly for 10 days [11]. Drosophila lifespan extension was documented at dietary concentrations from 0.001×10⁻⁶ to 5×10⁻⁶ wt.% [5] — vastly lower on a mass-concentration basis than the rodent injection doses. These differences reflect different route efficiencies, species metabolic rates, and experimental endpoints rather than a coherent dose-response curve.
Is Epitalon research only from one group, and has it been independently replicated?
The overwhelming majority of published Epitalon research — including all lifespan studies, the primate study, the retinitis pigmentosa clinical series, the circadian gene clinical study, and most mechanistic in vitro work — originates from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology or its close collaborators. Two published studies from independent groups are exceptions: Al-dulaimi et al. (2025) confirmed telomere extension in human cell lines via hTERT and ALT mechanisms using commercially sourced Epitalon [2], and Gatta et al. (2025) demonstrated antioxidant and anti-fibrotic effects in a human retinal cell diabetic retinopathy model [19]. The 2025 comprehensive review by Araj et al. [13] — from Polish and UK-affiliated authors — catalogued the published evidence without originating new in vivo data. Independent replication of lifespan, anti-tumor, and primate neuroendocrine findings has not been published.
What is the difference between Epitalon and Epithalamin?
Epithalamin is the polypeptide extract from bovine pineal gland that was the original research compound developed by the Khavinson group. It contains multiple peptide sequences and other bioactive molecules in a complex mixture. Epitalon is the four-amino-acid synthetic sequence (AEDG / Ala-Glu-Asp-Gly) isolated and identified as the probable active fragment within Epithalamin. Anisimov et al. compared both in Drosophila and rodent longevity studies; both produced lifespan-extending effects in those models, with Epitalon offering the advantage of a chemically defined, reproducible synthetic compound rather than a biological extract. Epithalamin is essentially unavailable commercially and has not been the subject of significant research outside the Khavinson program.
What research exists on Epitalon and cancer or tumor suppression?
Several rodent studies documented anti-tumor effects. In SHR mice, leukemia development was inhibited 6.0-fold in the Epitalon-treated group compared with controls [3]. In HER-2/neu transgenic mice, breast adenocarcinoma incidence decreased 1.6-fold, multiple-tumor animals decreased 2-fold, and tumor-free animals increased 3.7-fold; HER-2/neu mRNA was suppressed [4]. In rat colon carcinogenesis, tumor incidence and multiplicity in both colon segments were significantly reduced when Epitalon was administered throughout the carcinogen exposure period [6]. In C3H/He mice with spontaneous carcinomas, no metastases were found in the treated group versus 3 of 9 in controls [7]. All of these studies are from the Khavinson group. The 2025 Al-dulaimi study [2] added an important complexity: in cancer cell lines, Epitalon activates ALT telomere extension — an observation whose long-term implications for tumor biology remain unresolved.
What is the regulatory status of Epitalon?
Epitalon is not approved by the FDA, the European Medicines Agency, or any other major national regulatory authority for any human therapeutic or diagnostic indication. It is not classified as a dietary supplement and does not appear on any recognized pharmacopeia. WADA's S0 category (Non-Approved Substances) prohibits any pharmacological substance not approved by a governmental regulatory health authority in either therapeutic or non-therapeutic use; Epitalon falls within this category. No marketing authorization has been issued in the Russian Federation for Epitalon as a pharmaceutical product, despite the substantial portion of Epitalon research occurring within Russian institutions [13].
What recent (2024–2025) studies have been published on Epitalon?
Four studies appeared in 2025. Al-dulaimi et al. [2] provided the first independent confirmation of Epitalon's telomere-extending capacity in human cell lines, characterizing the differential hTERT vs. ALT mechanism across normal and cancer cells. Gatta et al. [19] showed Epitalon fully restored high-glucose-impaired wound healing in ARPE-19 human retinal pigment epithelial cells, with antioxidant gene rescue and EMT marker suppression. Araj et al. [13] published a comprehensive review synthesizing 25 years of published Epitalon evidence, confirming its presence in the human pineal gland via LC-MS/MS, and documenting the major outstanding evidence gaps. A bovine oocyte study [20] reported Epitalon-activated telomerase improved post-thaw blastocyst development and mitochondrial health in an assisted reproduction application.
Has Epitalon been studied in bone marrow or chromosomal stability?
Yes. In female SHR mice, Epitalon at 1 µg/mouse subcutaneously on a monthly 5-day cycle reduced bone marrow chromosomal aberrations by 17.1% (p<0.05) compared with untreated controls [3]. Similar antimutagenic findings were reported in SAMP-1 and SAMR-1 senescence-accelerated mice over 10 months [8][16]. Antimutagenic effects were also documented in human lymphocytes co-exposed to zinc, cobalt, and nickel in vitro [16]. The antimutagenic effect in the SHR study exceeded that of melatonin tested under the same protocol.
Does Epitalon affect immune function?
Some immune-related findings have been reported. At ultra-low concentrations (10⁻¹⁷–10⁻¹⁵ M, femtomolar range), Epitalon exhibited mitogenic activity in murine thymocytes — stimulating cell division — and comitogenic effects when combined with concanavalin A or recombinant IL-1β [13]. In mouse splenocytes, IL-2 mRNA levels elevated within 5 hours, more rapidly than the comparison peptide Vilon required (20 hours). In rats, a single intramuscular injection produced IL-2 mRNA elevation in the hypothalamus within 24 hours [13]. These findings are from the Khavinson group. Their relationship to functional immune protection in vivo — and to the anti-tumor findings in rodent models — has not been mechanistically resolved.
What epigenetic mechanisms have been proposed for Epitalon?
Molecular modeling studies have identified preferential binding of the AEDG peptide to histones H1/3 and H1/6 at DNA-interface sites [9]. Histone H1 variants regulate chromatin compaction and gene accessibility; binding at these sites could influence transcription factor access to gene promoters and thereby alter gene expression patterns without changing the DNA sequence itself. This epigenetic hypothesis is consistent with Epitalon's observed effects on neurogenic differentiation marker mRNA expression (1.6–1.8-fold increases in Nestin, GAP43, beta-Tubulin III, Doublecortin) in gingival mesenchymal stem cells [9], and with the reduction in senescence marker p16 and p21 expression in oral stem cells [10]. These are proposed mechanisms from in vitro and computational studies; epigenetic effects have not been characterized in a longitudinal in vivo setting.
Can Epitalon be taken orally?
This is an open question in the literature. Drosophila lifespan extension studies used dietary Epitalon supplementation in culture medium, establishing that the compound can exert biological effects when delivered via an oral/dietary route in an invertebrate model [5]. The structural properties of the peptide — two intramolecular salt bridges and proposed resistance to hydrolysis — are theoretically compatible with gastric survival. However, no formal oral bioavailability study in a mammalian model has been published [13]. Dendrimer complexes as potential oral delivery vehicles have been investigated computationally but not validated in vivo. The published human clinical studies used parabulbar injection [12] and sublingual administration [15] — routes that bypass first-pass hepatic metabolism — rather than oral capsule or tablet forms. Until mammalian pharmacokinetic data for oral delivery are published, oral bioavailability in humans remains uncharacterized.